Location History:
- Burlington, CA (2015 - 2022)
- Cambridge, MA (US) (2023)
Company Filing History:
Years Active: 2015-2025
Title: Christopher M. Lanthier: Innovating Pharmaceutical Processes
Introduction
Christopher M. Lanthier, an accomplished inventor based in Burlington, Canada, has significantly contributed to the field of pharmaceuticals with an impressive portfolio of six patents. His innovations focus on the preparation of key compounds used in the synthesis of therapeutic agents, showcasing his expertise and dedication to advancing medical science.
Latest Patents
Among Lanthier's latest patents is a process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid. This patent outlines methods and processes for preparing vadadustat and its pharmaceutically acceptable salts. Another notable patent details the preparation of [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters, and amides. This involves developing processes for creating derivatives, including 5-aryl and 5-heteroaryl substituted compounds. These compounds hold promise as prolyl hydroxylase inhibitors, potentially providing therapeutic benefits for various medical conditions.
Career Highlights
Christopher Lanthier currently works with Akebia Therapeutics, Inc., where he utilizes his innovative skills to contribute to the development of novel medical therapies. His ability to create efficient processes for synthesizing pharmaceutical compounds plays a crucial role in the company's research and development efforts.
Collaborations
Throughout his career, Lanthier has worked alongside talented individuals such as Boris Gorin and Jan Oudenes. These collaborations foster an environment of creativity and innovation, enabling the team to pursue groundbreaking projects in the pharmaceutical landscape.
Conclusion
Christopher M. Lanthier stands out as a key figure in the realm of pharmaceutical innovation. His six patents reflect a commitment to improving the synthesis of essential compounds for medical use. As he continues his journey at Akebia Therapeutics, Inc., his contributions are likely to pave the way for future advancements in drug development.